← Back to headlines
UBS Initiates Coverage on Jasper Therapeutics (JSPR) at Neutral
UBS has begun its coverage of Jasper Therapeutics (JSPR) with a 'Neutral' rating, despite acknowledging progress in the company's drug Briquilimab.
29 Mar, 20:50 — 29 Mar, 20:50
Sources
Showing 1 of 1 sources
